0001123292-17-000446.txt : 20170217 0001123292-17-000446.hdr.sgml : 20170217 20170217162938 ACCESSION NUMBER: 0001123292-17-000446 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170214 FILED AS OF DATE: 20170217 DATE AS OF CHANGE: 20170217 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Recro Pharma, Inc. CENTRAL INDEX KEY: 0001588972 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261523233 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (484) 395-2400 MAIL ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCP Vitalife Partners II LP CENTRAL INDEX KEY: 0001398330 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36329 FILM NUMBER: 17621766 BUSINESS ADDRESS: STREET 1: SUITE 190 STREET 2: 7 GREAT VALLEY PARKWAY CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (610) 995-2900 MAIL ADDRESS: STREET 1: SUITE 190 STREET 2: 7 GREAT VALLEY PARKWAY CITY: MALVERN STATE: PA ZIP: 19355 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2017-02-14 0001588972 Recro Pharma, Inc. REPH 0001398330 SCP Vitalife Partners II LP SUITE 190 7 GREAT VALLEY PARKWAY MALVERN PA 19355 0 0 1 0 Common Stock 2017-02-14 4 S 0 2293 7.9559 D 2312594 D Common Stock 2017-02-15 4 S 0 6479 7.88 D 2306115 D Common Stock 2017-02-16 4 S 0 3293 7.8572 D 2302882 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.90 to $8.01, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.78 to $7.93, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4. /s/ Donna Nichols, Attorney-in-fact 2017-02-17